Developer docs
API playgroundTry for free, no card

Search company profiles

AN2 Therapeutics

Full company profile

uuid0000ldb

Namestring
AN2 Therapeutics
Legal namestring
AN2 Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, and listed on NASDAQ under the ticker ANTX. Founded in 2017, the company is built around a proprietary boron chemistry drug discovery platform that exploits boron's distinctive ability to bind biological targets through reversible covalent bonds, enabling the design of small-molecule therapeutics against targets that have historically been difficult to inhibit with traditional carbon-based molecules. The platform produces a pipeline spanning hematologic, infectious, and oncologic diseases, with lead candidate epetraborole (an oral leucyl-tRNA synthetase inhibitor) advancing in three Phase 2 programs covering polycythemia vera, Mycobacterium abscessus complex lung disease, and a historical Phase II/III program for treatment-refractory MAC lung disease. Additional programs include AN2-502998 (oral Chagas disease candidate, Phase 1 complete with Phase 2 planned for late 2026 in collaboration with DNDi), two early-stage oncology programs targeting PI3Kα and ENPP1 expected to enter development in 2026, and global health programs in tuberculosis (in collaboration with GSK and funded by the Gates Foundation) and melioidosis (U.S. government-funded).

The company's business model is currently pre-commercial: there are no approved products, no product revenue, and the operating model centers on advancing pipeline assets through clinical development toward eventual commercialization. Capital is raised primarily through dilutive equity financings, including a $70M underwritten public offering in August 2023, a $40M private placement in March 2026 from Coastlands Capital, Commodore Capital, and Vivo Capital, and an $80M at-the-market sales agreement with Jefferies established in April 2026. Non-dilutive grant funding from the Bill & Melinda Gates Foundation (into its third year in 2025) and U.S. government sources support global health programs. Strategic licensing and co-development partnerships — with Brii Biosciences for epetraborole rights in China, Hong Kong, Taiwan, and Macau; with DNDi for Chagas disease; and with GSK for tuberculosis — define the company's distribution and development channels for non-U.S. geographies and global health indications. Following an August 2024 50% workforce reduction triggered by the failure of the lead MAC lung disease Phase II/III trial, the company operates with a leaner cost base (FY2025 net loss of $35.2M vs. $51.3M in FY2024; R&D expenses of $24.8M vs. $40.5M) and approximately $60M of cash on hand, with runway extended into 2029 by the March 2026 financing.

Short descriptiontext

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing oral boron-based small-molecule therapeutics for rare infectious diseases (M. abscessus, Chagas), hematologic conditions (polycythemia vera), and oncology, using its proprietary boron chemistry platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, boron chemistry therapeutics, infectious disease drug development, rare disease therapeutics, small-molecule drug discovery
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Equity / capital raises
TypeSubscription Recurring
Description

Clinical-stage biotech with no commercial product revenue; finances operations primarily through equity financing including private placements (e.g., $40M in March 2026 from Coastlands Capital, Commodore Capital, Vivo Capital), at-the-market (ATM) sales agreement with Jefferies ($80M facility in April 2026), underwritten stock offerings (e.g., $70M in August 2023), and stock option exercises.

biospace.com
2Non-dilutive grant funding
TypeLicensing Royalties
Description

Research grants from the Bill & Melinda Gates Foundation supporting boron-based therapy discovery for tuberculosis and malaria (aminoacyl-tRNA synthetase inhibitors). U.S. government funding for melioidosis program. Funding primarily non-dilutive and tied to global health initiatives.

investor.an2therapeutics.com
3Out-licensing (future / current)
TypeLicensing Royalties
Description

Strategic licensing arrangement with Brii Biosciences granting rights to develop, manufacture, and commercialize certain compounds including epetraborole in China, Hong Kong, Taiwan, and Macau. Future licensing/royalty revenue from any approved products in out-licensed territories.

an2therapeutics.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Epetraborole
Description

Investigational oral boron-based small-molecule antibacterial (leucyl-tRNA synthetase inhibitor) being developed by AN2 for polycythemia vera and Mycobacterium abscessus complex lung disease.

an2therapeutics.com
+1 more record
Core offering1 text field

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing boron-based small-molecule therapeutics using its proprietary boron chemistry drug discovery platform. Its lead candidate is oral epetraborole, a leucyl-tRNA synthetase (LeuRS) inhibitor being advanced in Phase 2 studies for polycythemia vera, Mycobacterium abscessus lung disease, and historically treatment-refractory MAC lung disease. The pipeline also includes AN2-502998 for chronic Chagas disease, early-stage oncology programs targeting PI3Kα and ENPP1, and global health programs for tuberculosis and melioidosis supported by the Gates Foundation and U.S. government.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100% parasite elimination in nonhuman primates with chronic Chagas disease after 28-day treatment at target human-achievable exposures (AN2-502998)
+5 more records
Product overview1 text field

AN2 Therapeutics is a clinical-stage biopharmaceutical company built around a single core technology — its proprietary boron chemistry drug discovery platform — which powers a portfolio of small-molecule therapeutic candidates spanning hematologic diseases, infectious diseases, and oncology. The platform-based architecture generates discrete pipeline products including the lead clinical asset oral epetraborole (a leucyl-tRNA synthetase inhibitor advancing in three Phase 2 programs: polycythemia vera, M. abscessus lung disease, and the historical EBO-301 program for TR-MAC lung disease), the oral Chagas disease candidate AN2-502998 (in Phase 1 with Phase 2 planned), early-stage oncology programs targeting PI3Kα and ENPP1, and global health programs for melioidosis (U.S. government-funded) and tuberculosis (in collaboration with GSK and supported by the Gates Foundation). Global health initiatives are advanced primarily through non-dilutive funding from foundations and public agencies, while commercial-stage indications are funded through equity financings including a March 2026 $40 million private placement and a prior $70 million underwritten offering.

Product and service5 records
1Epetraborole (oral)
CategoryClinical-stage therapeutic candidate
2AN2-502998 (oral)
CategoryClinical-stage therapeutic candidate
3Boron-based Oncology Programs (PI3Kα and ENPP1)
CategoryDiscovery-stage research programs
4Melioidosis Program
CategoryGlobal health research program
5Tuberculosis Program
CategoryGlobal health research program
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Strategic partnership in which Brii Biosciences has licensed rights to develop, manufacture, and commercialize certain AN2 compounds, including epetraborole, in China, Hong Kong, Taiwan, and Macau. Brii is a clinical-stage company committed to serving patients' needs and improving public health in China and around the world.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration announced November 2025 to advance boron-based LeuRS-inhibitors targeting tuberculosis (TB). Project supported by Gates Foundation (which is funding its third year of the program). Aims to address the global health challenge posed by TB using novel boron chemistry approaches.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partnership for AN2-502998 in Chagas disease. AN2 plans to initiate a Phase 2 proof-of-concept study late 2026 in collaboration with DNDi. If approved, AN2-502998 would become the first FDA-approved therapy for adults with chronic Chagas disease, which affects over 300,000 people in the U.S. and approximately 10 million globally.

4Oregon Health and Sciences University (OHSU)
Strategic tierMajorTypeImplementation/ SI/ Consulting Partner
Description

Investigator-initiated study partnership for Phase 2 evaluation of epetraborole in M. abscessus complex lung disease. Multicenter, randomized, double-blind, placebo-controlled, prospective clinical study led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at OHSU, with investigators across 10-15 sites in the U.S.

businesswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established commercial-stage biopharmaceutical company with Arikayce, the only FDA-approved therapy specifically indicated for refractory MAC lung disease — directly competing with AN2's epetraborole in the NTM lung disease space. Broader incumbent in rare pulmonary and infectious diseases with full commercial infrastructure AN2 would need to build.

TypeRegional player
Description

Clinical-stage biopharmaceutical company committed to serving patient needs in China and globally. Licensed rights from AN2 to develop, manufacture, and commercialize epetraborole in China, Hong Kong, Taiwan, and Macau. Comparable as a partner / regional player addressing the same molecule in a specific geographic market.

TypeEmerging player
Description

Private clinical-stage pharmaceutical company developing novel antibiotics to combat MDR bacterial infections, including collaborations with Global Antibiotic R&D Partnership (GARDP). Comparable as a privately funded anti-infectives developer targeting indications with limited treatment options, supported by non-dilutive global health funding.

TypeBroad incumbent
Description

Acquired Anacor Pharmaceuticals (AN2's founding team and boron chemistry platform) for $5.2B in 2016 and commercialized the resulting boron-based drugs KERYDIN and EUCRISA. As the dominant incumbent in boron chemistry drug development, Pfizer represents both a potential acquirer and a competitive threat to AN2's boron chemistry IP position.

TypeDirect peer
Description

Clinical-stage biotechnology company developing direct lytic agents and other anti-infectives for serious bacterial infections including MRSA bacteremia and pneumonia. Comparable as a small public infectious disease biotech targeting drug-resistant and difficult-to-treat pathogens.

TypeDirect peer
Description

Clinical-stage biotechnology company developing anti-infectives including antiviral conjugates and immunotherapy approaches for serious infections. Comparable as a small public anti-infectives biotech with a similarly focused pipeline of differentiated small molecules and biologics targeting serious infectious diseases.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing anti-infective therapies for rare and serious bacterial infections, including NTM lung disease and MDR gram-negative infections. Most directly comparable as a small-cap public biotech with similar pipeline breadth in infectious disease and comparable reliance on dilutive financings and partnership-driven economics.

TypeDirect peer
Description

Clinical-stage anti-infectives company developing oral antibiotics for complicated urinary tract infections and other MDR bacterial infections. Directly comparable as a micro-cap public anti-infectives biotech with similar business model (in-licensed / developed antibiotics with potential for FDA approval in indications lacking treatment options).

TypeEmerging player
Description

Non-profit product development partnership focused on neglected tropical diseases including Chagas disease. Co-developing AN2-502998 for chronic Chagas Phase 2. DNDi is both a partner and a parallel developer of Chagas therapies, making it a partial peer in the neglected-disease drug development ecosystem.

TypeEmerging player
Description

Non-profit product development partnership developing novel tuberculosis treatments. Overlaps with AN2's TB program via Melvin Spigelman (TB Alliance CEO) sitting on AN2's board. Comparable as a co-development partner and parallel developer of novel TB regimens leveraging novel mechanisms of action.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AN2 Therapeutics

Biopharmaceutical Therapeuticsan2therapeutics.com

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing oral boron-based small-molecule therapeutics for rare infectious diseases (M. abscessus, Chagas), hematologic conditions (polycythemia vera), and oncology, using its proprietary boron chemistry platform.

What AN2 Therapeutics does

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, and listed on NASDAQ under the ticker ANTX. Founded in 2017, the company is built around a proprietary boron chemistry drug discovery platform that exploits boron's distinctive ability to bind biological targets through reversible covalent bonds, enabling the design of small-molecule therapeutics against targets that have historically been difficult to inhibit with traditional carbon-based molecules. The platform produces a pipeline spanning hematologic, infectious, and oncologic diseases, with lead candidate epetraborole (an oral leucyl-tRNA synthetase inhibitor) advancing in three Phase 2 programs covering polycythemia vera, Mycobacterium abscessus complex lung disease, and a historical Phase II/III program for treatment-refractory MAC lung disease. Additional programs include AN2-502998 (oral Chagas disease candidate, Phase 1 complete with Phase 2 planned for late 2026 in collaboration with DNDi), two early-stage oncology programs targeting PI3Kα and ENPP1 expected to enter development in 2026, and global health programs in tuberculosis (in collaboration with GSK and funded by the Gates Foundation) and melioidosis (U.S. government-funded).

The company's business model is currently pre-commercial: there are no approved products, no product revenue, and the operating model centers on advancing pipeline assets through clinical development toward eventual commercialization. Capital is raised primarily through dilutive equity financings, including a $70M underwritten public offering in August 2023, a $40M private placement in March 2026 from Coastlands Capital, Commodore Capital, and Vivo Capital, and an $80M at-the-market sales agreement with Jefferies established in April 2026. Non-dilutive grant funding from the Bill & Melinda Gates Foundation (into its third year in 2025) and U.S. government sources support global health programs. Strategic licensing and co-development partnerships — with Brii Biosciences for epetraborole rights in China, Hong Kong, Taiwan, and Macau; with DNDi for Chagas disease; and with GSK for tuberculosis — define the company's distribution and development channels for non-U.S. geographies and global health indications. Following an August 2024 50% workforce reduction triggered by the failure of the lead MAC lung disease Phase II/III trial, the company operates with a leaner cost base (FY2025 net loss of $35.2M vs. $51.3M in FY2024; R&D expenses of $24.8M vs. $40.5M) and approximately $60M of cash on hand, with runway extended into 2029 by the March 2026 financing.

AN2 Therapeutics firmographics

Firmographics
Name
AN2 Therapeutics
Legal name
AN2 Therapeutics, Inc.
Website
https://an2therapeutics.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing oral boron-based small-molecule therapeutics for rare infectious diseases (M. abscessus, Chagas), hematologic conditions (polycythemia vera), and oncology, using its proprietary boron chemistry platform.
Ownership category
akta.pro rank

AN2 Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage biopharmaceuticals
  • Boron chemistry therapeutics
  • Infectious disease drug development
  • Rare disease therapeutics
  • Small-molecule drug discovery

Where AN2 Therapeutics is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AN2 Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Equity / capital raises: Clinical-stage biotech with no commercial product revenue; finances operations primarily through equity financing including private placements (e.g., $40M in March 2026 from Coastlands Capital, Commodore Capital, Vivo Capital), at-the-market (ATM) sales agreement with Jefferies ($80M facility in April 2026), underwritten stock offerings (e.g., $70M in August 2023), and stock option exercises.
  2. Non-dilutive grant funding: Research grants from the Bill & Melinda Gates Foundation supporting boron-based therapy discovery for tuberculosis and malaria (aminoacyl-tRNA synthetase inhibitors). U.S. government funding for melioidosis program. Funding primarily non-dilutive and tied to global health initiatives.
  3. Out-licensing (future / current): Strategic licensing arrangement with Brii Biosciences granting rights to develop, manufacture, and commercialize certain compounds including epetraborole in China, Hong Kong, Taiwan, and Macau. Future licensing/royalty revenue from any approved products in out-licensed territories.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

AN2 Therapeutics product offering

Product offering

Core offering

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing boron-based small-molecule therapeutics using its proprietary boron chemistry drug discovery platform. Its lead candidate is oral epetraborole, a leucyl-tRNA synthetase (LeuRS) inhibitor being advanced in Phase 2 studies for polycythemia vera, Mycobacterium abscessus lung disease, and historically treatment-refractory MAC lung disease. The pipeline also includes AN2-502998 for chronic Chagas disease, early-stage oncology programs targeting PI3Kα and ENPP1, and global health programs for tuberculosis and melioidosis supported by the Gates Foundation and U.S. government.

Product overview

AN2 Therapeutics is a clinical-stage biopharmaceutical company built around a single core technology — its proprietary boron chemistry drug discovery platform — which powers a portfolio of small-molecule therapeutic candidates spanning hematologic diseases, infectious diseases, and oncology. The platform-based architecture generates discrete pipeline products including the lead clinical asset oral epetraborole (a leucyl-tRNA synthetase inhibitor advancing in three Phase 2 programs: polycythemia vera, M. abscessus lung disease, and the historical EBO-301 program for TR-MAC lung disease), the oral Chagas disease candidate AN2-502998 (in Phase 1 with Phase 2 planned), early-stage oncology programs targeting PI3Kα and ENPP1, and global health programs for melioidosis (U.S. government-funded) and tuberculosis (in collaboration with GSK and supported by the Gates Foundation). Global health initiatives are advanced primarily through non-dilutive funding from foundations and public agencies, while commercial-stage indications are funded through equity financings including a March 2026 $40 million private placement and a prior $70 million underwritten offering.

Differentiator

Problem solved

Functional benefit

Brands

  • Epetraborole: Investigational oral boron-based small-molecule antibacterial (leucyl-tRNA synthetase inhibitor) being developed by AN2 for polycythemia vera and Mycobacterium abscessus complex lung disease.
  • AN2-502998

Products and services

  • Epetraborole (oral)
  • AN2-502998 (oral)
  • Boron-based Oncology Programs (PI3Kα and ENPP1)
  • Melioidosis Program
  • Tuberculosis Program

Quantifiable outcome

  • 100% parasite elimination in nonhuman primates with chronic Chagas disease after 28-day treatment at target human-achievable exposures (AN2-502998)
  • +5 more outcomes

Companies that use AN2 Therapeutics

Customer profile

Segments5 records

Ideal customer profiles3 records

AN2 Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AN2 Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Brii BiosciencescoreOEM/ Whitelabel/ Licensing PartnerStrategic partnership in which Brii Biosciences has licensed rights to develop, manufacture, and commercialize certain AN2 compounds, including epetraborole, in China, Hong Kong, Taiwan, and Macau. Brii is a clinical-stage company committed to serving patients' needs and improving public health in China and around the world.
  • GSK (GlaxoSmithKline)coreStrategic or Co-development PartnerResearch collaboration announced November 2025 to advance boron-based LeuRS-inhibitors targeting tuberculosis (TB). Project supported by Gates Foundation (which is funding its third year of the program). Aims to address the global health challenge posed by TB using novel boron chemistry approaches.
  • Drugs for Neglected Disease initiative (DNDi)coreStrategic or Co-development PartnerCo-development partnership for AN2-502998 in Chagas disease. AN2 plans to initiate a Phase 2 proof-of-concept study late 2026 in collaboration with DNDi. If approved, AN2-502998 would become the first FDA-approved therapy for adults with chronic Chagas disease, which affects over 300,000 people in the U.S. and approximately 10 million globally.
  • Oregon Health and Sciences University (OHSU)majorImplementation/ SI/ Consulting PartnerInvestigator-initiated study partnership for Phase 2 evaluation of epetraborole in M. abscessus complex lung disease. Multicenter, randomized, double-blind, placebo-controlled, prospective clinical study led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at OHSU, with investigators across 10-15 sites in the U.S.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

AN2 Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Insmed Incorporated: Established commercial-stage biopharmaceutical company with Arikayce, the only FDA-approved therapy specifically indicated for refractory MAC lung disease — directly competing with AN2's epetraborole in the NTM lung disease space. Broader incumbent in rare pulmonary and infectious diseases with full commercial infrastructure AN2 would need to build.
  • Pfizer Inc. Acquired Anacor Pharmaceuticals (AN2's founding team and boron chemistry platform) for $5.2B in 2016 and commercialized the resulting boron-based drugs KERYDIN and EUCRISA. As the dominant incumbent in boron chemistry drug development, Pfizer represents both a potential acquirer and a competitive threat to AN2's boron chemistry IP position.

Regional players

  • Brii Biosciences: Clinical-stage biopharmaceutical company committed to serving patient needs in China and globally. Licensed rights from AN2 to develop, manufacture, and commercialize epetraborole in China, Hong Kong, Taiwan, and Macau. Comparable as a partner / regional player addressing the same molecule in a specific geographic market.

Emerging players

  • VenatoRx Pharmaceuticals: Private clinical-stage pharmaceutical company developing novel antibiotics to combat MDR bacterial infections, including collaborations with Global Antibiotic R&D Partnership (GARDP). Comparable as a privately funded anti-infectives developer targeting indications with limited treatment options, supported by non-dilutive global health funding.
  • Drugs for Neglected Diseases initiative (DNDi): Non-profit product development partnership focused on neglected tropical diseases including Chagas disease. Co-developing AN2-502998 for chronic Chagas Phase 2. DNDi is both a partner and a parallel developer of Chagas therapies, making it a partial peer in the neglected-disease drug development ecosystem.
  • TB Alliance (Global Alliance for TB Drug Development): Non-profit product development partnership developing novel tuberculosis treatments. Overlaps with AN2's TB program via Melvin Spigelman (TB Alliance CEO) sitting on AN2's board. Comparable as a co-development partner and parallel developer of novel TB regimens leveraging novel mechanisms of action.

Direct peers

  • ContraFect Corporation: Clinical-stage biotechnology company developing direct lytic agents and other anti-infectives for serious bacterial infections including MRSA bacteremia and pneumonia. Comparable as a small public infectious disease biotech targeting drug-resistant and difficult-to-treat pathogens.
  • Cidara Therapeutics: Clinical-stage biotechnology company developing anti-infectives including antiviral conjugates and immunotherapy approaches for serious infections. Comparable as a small public anti-infectives biotech with a similarly focused pipeline of differentiated small molecules and biologics targeting serious infectious diseases.
  • Spero Therapeutics: Clinical-stage biopharmaceutical company developing anti-infective therapies for rare and serious bacterial infections, including NTM lung disease and MDR gram-negative infections. Most directly comparable as a small-cap public biotech with similar pipeline breadth in infectious disease and comparable reliance on dilutive financings and partnership-driven economics.
  • Iterum Therapeutics: Clinical-stage anti-infectives company developing oral antibiotics for complicated urinary tract infections and other MDR bacterial infections. Directly comparable as a micro-cap public anti-infectives biotech with similar business model (in-licensed / developed antibiotics with potential for FDA approval in indications lacking treatment options).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

AN2 Therapeutics social profiles

Digital presence

AN2 Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AN2 Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

AN2 Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AN2 Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AN2 Therapeutics

What does AN2 Therapeutics do?

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing boron-based small-molecule therapeutics using its proprietary boron chemistry drug discovery platform. Its lead candidate is oral epetraborole, a leucyl-tRNA synthetase (LeuRS) inhibitor being advanced in Phase 2 studies for polycythemia vera, Mycobacterium abscessus lung disease, and historically treatment-refractory MAC lung disease. The pipeline also includes AN2-502998 for chronic Chagas disease, early-stage oncology programs targeting PI3Kα and ENPP1, and global health programs for tuberculosis and melioidosis supported by the Gates Foundation and U.S. government.

Is AN2 Therapeutics a public or private company?

AN2 Therapeutics is a public company. It is classified as public and is currently operating.

When was AN2 Therapeutics founded?

AN2 Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is AN2 Therapeutics based?

AN2 Therapeutics is headquartered in Menlo Park, United States, in the North America region.

How does AN2 Therapeutics make money?

Three revenue lines are on record. Equity / capital raises are the primary driver. The others are non-dilutive grant funding and out-licensing (future / current).

Who are AN2 Therapeutics's main competitors?

Broad incumbents on record are Insmed Incorporated and Pfizer Inc.. Brii Biosciences is listed as a regional player. Emerging players are VenatoRx Pharmaceuticals, Drugs for Neglected Diseases initiative (DNDi) and TB Alliance (Global Alliance for TB Drug Development). Direct peers are ContraFect Corporation, Cidara Therapeutics, Spero Therapeutics and Iterum Therapeutics.

Does AN2 Therapeutics have an API?

No public API is recorded for AN2 Therapeutics.

What industry is AN2 Therapeutics in?

AN2 Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerAN2 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026AN2 Therapeutics reported a Q3 net loss of $7.96 million, down from $9.35 million a year ago, and a nine-month net loss of $26.17 million, down from $26.46 million. Basic and diluted loss per share from continuing operations were $0.17 and $0.63, respectively, compared to $0.31 and $0.88 a year ago.Business Wire BlogAN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)AN2 Therapeutics granted inducement equity awards to two newly hired employees on October 19, 2026, totaling 10,565 options and 5,283 RSUs. The options have an exercise price of $3.37 per share, with vesting over one year and 48 months, and RSUs vest annually over four years.FinancialContent Business PageAN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)AN2 Therapeutics granted inducement equity awards to two newly hired employees on October 19, 2026, including options for 10,565 shares and 5,283 RSUs. The awards, priced at $3.37 per share, vest over four years and were approved under Nasdaq Listing Rule 5635(c)(4).TradingViewAN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)AN2 Therapeutics granted inducement equity awards to two newly hired employees on October 19, 2026, including options and RSUs. The awards, totaling 10,565 options and 5,283 RSUs, were approved under Nasdaq Listing Rule 5635(c)(4) and vest over one year and four years.PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)Purcell & Lefkowitz LLP announced an investigation of AN2 Therapeutics on behalf of shareholders, seeking to determine whether directors breached fiduciary duties in recent corporate actions. The firm offers free consultation to shareholders interested in their rights and options.Pulse 2.0AN2 Therapeutics Secures Extended Gates Foundation Funding For GSK Tuberculosis CollaborationAN2 Therapeutics received an extension of Gates Foundation funding to support its tuberculosis research collaboration with GSK. The funds will develop boron-based LeuRS inhibitors, with LeuRS being a clinically validated target. The collaboration aims to address the continued need for new TB treatments.Stock TitanAN2 Therapeutics gets Gates funding extension for TBAN2 Therapeutics announced an extension of Gates Foundation funding to support its tuberculosis research collaboration with GSK on boron-based LeuRS inhibitors. The funding will advance development of these inhibitors for TB treatment, with LeuRS also being a target for other drugs in development.BioSpaceAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKAN2 Therapeutics announced the Gates Foundation extended funding for its tuberculosis research collaboration with GSK, focusing on boron-based LeuRS inhibitors. The company cited TB as a leading infectious disease killer, with 10.7 million cases in 2024. The collaboration aims to advance new treatment options for tuberculosis.Seeking AlphaAN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX)AN2 Therapeutics is rated a speculative buy by Eljaye Tellis, with a risk-adjusted base-case valuation of about $12 per share versus its September 18 closing price of $5.05. The rating hinges on epetraborole's potential for polycythemia vera, despite its failure in MAC lung disease. Additional programs for M. abscessus and Chagas provide optionality.YahooAN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)AN2 Therapeutics granted inducement equity awards to newly appointed Chief Medical Officer Cameron Trenor, including a stock option for 233,333 shares and restricted stock units for 116,667 shares. The option has a $5.36 exercise price and a 10-year term, with vesting over four years. The awards were approved by the Compensation Committee under NASDAQ Rule 5635(c)(4).